https://staging.pauljanssenfuturelab.eu/Resource/qoq/2016-10-27T18:45:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/716-2/2016-10-27T18:46:51+02:00https://staging.pauljanssenfuturelab.eu/Resource/flowpaper-test/2016-10-31T13:01:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/template-outline-development-plan/2016-10-31T12:08:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/excel/2016-10-31T14:52:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/contraceptive-case-study/2016-10-31T16:33:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/hartmann-and-hassan/2016-11-02T18:09:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/kola-and-landis/2016-11-02T18:10:20+02:00https://staging.pauljanssenfuturelab.eu/Resource/a-real-option-perspective-on-valuing-gas-fields/2016-11-03T10:47:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/unlocking-the-value-of-real-options/2016-11-10T13:11:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/tufts-university-center-for-the-study-of-drug-development/2016-11-22T11:09:12+02:00https://staging.pauljanssenfuturelab.eu/Resource/questions-optimizing-calculator/2017-08-31T15:24:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/us-food-and-drug-administration/2016-11-22T11:10:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/phrma/2017-03-27T14:38:15+02:00https://staging.pauljanssenfuturelab.eu/Resource/developing-drug-prototypes/2016-11-07T15:19:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/better-decision-making-for-evaluating-new-medical-device-projects/2016-11-07T18:51:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/halted-development-of-non-sedating-anxiolytic/2017-03-29T17:49:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/pet-study-merck-case-study/2017-03-29T17:51:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/paul-janssen-futurelab-leiden-2/2017-03-27T14:39:02+02:00https://staging.pauljanssenfuturelab.eu/Resource/nutrion-and-pharma-narrowing-the-gap/2016-11-09T19:02:01+02:00https://staging.pauljanssenfuturelab.eu/Resource/putting-a-price-on-biotechnology-1/2016-11-09T19:03:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/putting-a-price-on-biotechnology-2/2016-11-09T19:04:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/probiotics/2017-03-29T17:59:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/besselink-lancet/2017-08-28T13:30:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/besselink-lancet-discussion/2017-03-29T18:15:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/contraception-2003/2017-10-25T10:40:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/renal-denervation-trial-data/2016-11-10T15:43:02+02:00https://staging.pauljanssenfuturelab.eu/Resource/renal-deneravation-simplicity-video/2017-03-29T17:58:12+02:00https://staging.pauljanssenfuturelab.eu/Resource/htn3-24-hours-ambulatory-blood-pressure/2016-11-10T16:28:42+02:00https://staging.pauljanssenfuturelab.eu/Resource/htn-3-trial-results/2016-11-10T16:29:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/htn-3-post-hoc-analysis/2016-11-10T16:28:07+02:00https://staging.pauljanssenfuturelab.eu/Resource/can-the-pharmaceutical-industry-reduce-attrition-rates/2017-03-29T17:29:26+02:00https://staging.pauljanssenfuturelab.eu/Resource/real-options-for-pharmaceutical-rd-project-valuation/2017-03-29T17:32:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/better-decision-making-for-evaluating-new-medical-device-projects-2/2017-03-29T16:31:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/pharma-nutrition-interface-the-gap-is-narrowing/2017-03-29T17:24:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/putting-a-price-on-biotechnology/2017-03-29T17:19:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/putting-a-price-on-biotechnology-correspondence-and-reply/2017-03-29T17:22:18+02:00https://staging.pauljanssenfuturelab.eu/Resource/developing-drug-prototypes-2/2017-03-29T17:26:06+02:00https://staging.pauljanssenfuturelab.eu/Resource/nejm-2014-editorial-htn-3-trial/2016-12-08T15:50:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/nejm-2014-htn-3-trial-results/2016-12-08T15:54:31+02:00https://staging.pauljanssenfuturelab.eu/Resource/lancet-2010-comment-htn-2-trial/2016-12-08T15:53:58+02:00https://staging.pauljanssenfuturelab.eu/Resource/lancet-2010-hnt-2-trial-results/2016-12-08T16:47:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/ibm-institute-business-value/2019-10-17T09:49:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/2766-2/2017-03-29T17:43:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/2833-2/2017-04-28T13:54:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/rnpv-excel-whorksheet/2017-04-15T04:55:42+02:00https://staging.pauljanssenfuturelab.eu/Resource/development-outline-case-1/2017-04-05T16:28:21+02:00https://staging.pauljanssenfuturelab.eu/Resource/development-outline-case-2/2017-04-05T16:28:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/development-outline-case-3/2017-04-05T16:29:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/development-outline-case-4/2017-04-05T16:29:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/3164-2/2017-03-29T17:19:12+02:00https://staging.pauljanssenfuturelab.eu/Resource/nejm-2016-human-intestinal-microbiome-health-disease/2019-10-16T10:17:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/european-medicines-agency/2017-04-12T10:06:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/3304/2017-04-13T10:04:34+02:00https://staging.pauljanssenfuturelab.eu/Resource/human-microbiome-guts-glory/2017-04-13T10:02:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/lancet-2008-letters/2017-04-20T14:17:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/hawthorne-effect-wikipedia/2017-05-03T13:21:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/clinical-development-success-rates-2006-2015-bio-biomedtracker/2017-05-18T09:37:49+02:00https://staging.pauljanssenfuturelab.eu/Resource/2014-nature-biotech-success-rates-clinical-development/2017-05-18T09:38:53+02:00https://staging.pauljanssenfuturelab.eu/Resource/wipo-link-patent-cooperation-treaty/2017-05-22T12:19:58+02:00https://staging.pauljanssenfuturelab.eu/Resource/get-european-patent/2019-10-16T15:00:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-process-overview-usa/2019-10-16T15:00:12+02:00https://staging.pauljanssenfuturelab.eu/Resource/unified-patent-court/2017-05-29T10:53:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/the-unitary-patent/2017-05-29T10:50:24+02:00https://staging.pauljanssenfuturelab.eu/Resource/4185/2017-05-29T21:17:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/1-patent-value/2018-04-04T15:41:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/2-managing-patent-costs-wipo/2018-04-04T15:43:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/practical-steps-builiding-strong-ls-patent-portfolio/2019-10-23T12:06:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/4-key-issues-building-strong-life-sciences-patent-portfolio/2019-10-23T12:04:39+02:00https://staging.pauljanssenfuturelab.eu/Resource/4339/2018-04-05T10:49:34+02:00https://staging.pauljanssenfuturelab.eu/Resource/4384/2020-09-16T08:58:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/4434/2017-06-08T10:06:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/closing-the-deal/2017-06-12T12:17:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/the-value-of-royalty/2020-09-16T12:11:49+02:00https://staging.pauljanssenfuturelab.eu/Resource/review-global-biopharmaceutical-royalty-rates/2017-06-12T16:26:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/setting-values-royalty-rates-medical-life-sciences-business/2017-06-12T16:27:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/license-agreement/2017-06-28T16:11:44+02:00https://staging.pauljanssenfuturelab.eu/Resource/patenting-the-life-sciences-epo/2017-06-29T10:51:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/patenting-in-the-usa/2017-06-29T11:00:06+02:00https://staging.pauljanssenfuturelab.eu/Resource/instructions-template-research-protocol-may-2012/2017-08-25T17:35:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/template-research-protocol-ccmo/2019-05-29T12:42:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-website-device-development-process/2017-08-28T09:54:58+02:00https://staging.pauljanssenfuturelab.eu/Resource/instructive-reading-reef-biotech-prep-assignment/2019-05-02T12:08:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/spreadsheet-reef-biotech-prep-assignment/2017-08-29T18:19:32+02:00https://staging.pauljanssenfuturelab.eu/Resource/development-outline/2017-09-06T16:00:50+02:00https://staging.pauljanssenfuturelab.eu/Resource/powerpoint-andreas/2017-09-12T09:26:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/assignment-details/2017-09-13T08:49:42+02:00https://staging.pauljanssenfuturelab.eu/Resource/immunothera-case-really-happened/2017-09-13T17:18:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/intro-extended-course/2017-09-15T14:08:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/paul-janssen-futurelab-stipendium/2017-09-21T20:42:15+02:00https://staging.pauljanssenfuturelab.eu/Resource/campus-extended-submission-research-dossier/2017-09-21T20:42:39+02:00https://staging.pauljanssenfuturelab.eu/Resource/european-patent-convention-epc/2017-12-03T04:29:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/biomedicines-2016-complementary-approaches-existing-target-based-drug-discovery-identifying-novel-drug-targets/2018-03-05T13:21:07+02:00https://staging.pauljanssenfuturelab.eu/Resource/committee-finder/2018-03-12T10:19:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/around-the-block/2020-09-11T10:41:53+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-task-2/2020-10-01T11:36:56+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-task-4/2018-11-21T12:24:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-task-3/2020-10-01T11:43:11+02:00https://staging.pauljanssenfuturelab.eu/Resource/ip-assignment-1-ntziachristos-et-al-nature-biotech-2005/2018-11-21T12:51:08+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-andersson-engels/2018-11-21T12:49:17+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-carver/2018-11-21T12:48:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-mahmood/2018-11-21T12:48:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-xu-heng/2018-11-21T13:21:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-ntziachristos-2/2018-11-21T12:47:54+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-ntziachristos-1/2018-11-21T12:47:24+02:00https://staging.pauljanssenfuturelab.eu/Resource/clinical-development-campus-extended-course/2018-06-08T11:30:33+02:00https://staging.pauljanssenfuturelab.eu/Resource/jasmijn-timp/2018-06-12T12:25:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/reef-biotech-really-happened/2018-07-02T11:20:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/reef-biotech-introduction/2018-07-02T11:21:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/reef-biotech-authority-advice/2018-07-02T11:22:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/roche-really-happened/2018-07-02T14:41:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/younanamab-case-npv-rnpv-calculations-phase-based-according-original-development-plan/2018-07-26T11:12:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/younanamab-case-npv-rnpv-calculations-question-based-risks-costs-according-development-team/2018-07-26T11:12:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/younanamab-case-npv-rnpv-calculations-question-based-risks-costs-evenly-spread/2018-07-26T11:59:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/younanamab-case-qoc-output-phase-based-approach-according-original-development-plan-pdf/2018-07-26T11:14:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/younanamab-case-qoc-output-question-based-risks-costs-according-team-pdf/2018-07-26T11:15:01+02:00https://staging.pauljanssenfuturelab.eu/Resource/younanamab-case-qoc-output-question-based-risks-costs-evenly-spread-pdf/2018-07-26T11:52:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-breast-cancer-2017/2018-11-07T17:14:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-breast-2017/2018-10-17T13:59:18+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-us-patent-9707237-b2/2018-11-07T17:12:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-eu-patent-ep-2-445-911-b1/2018-11-07T17:24:42+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-claim-figure-1/2018-11-07T17:55:23+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-claim-figure-2/2018-11-07T17:54:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-ammended-ep-claims-2012/2018-11-08T11:58:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/website-surgvision/2018-11-15T09:45:33+02:00https://staging.pauljanssenfuturelab.eu/Resource/crispr-broad-patent-decision/2018-11-15T16:38:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-nature-communications-2018/2018-11-19T17:56:06+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-taks-1/2018-11-19T17:31:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/wipo-global-design-database/2018-11-19T17:36:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/wipo-global-brand-database/2018-11-19T17:37:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-trademark-electronic-search-system/2018-11-19T17:40:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-wo2011098101a1/2018-11-21T10:38:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-us9918640b2/2018-11-21T12:26:45+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-ep2359745a1/2018-11-21T12:27:49+02:00https://staging.pauljanssenfuturelab.eu/Resource/ib-de-risk-tool/2019-01-23T17:26:55+02:00https://staging.pauljanssenfuturelab.eu/Resource/cohen-annu-rev-pharmacol-toxicol-2015/2019-01-28T14:41:39+02:00https://staging.pauljanssenfuturelab.eu/Resource/brca1-us-patent-574282/2019-01-30T16:24:33+02:00https://staging.pauljanssenfuturelab.eu/Resource/patentability-genes-european-union-perspective/2019-01-30T16:55:51+02:00https://staging.pauljanssenfuturelab.eu/Resource/patentabilitypriorart_zammit/2019-01-31T12:15:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/patentability-antibodies-germinario-nature-2018/2019-02-14T14:35:25+02:00https://staging.pauljanssenfuturelab.eu/Resource/myriad-5-years-line-aboy-nature-biotech-2018/2019-02-14T15:03:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/patenting-vs-publishing-reed-nature-immunol-2013/2019-02-14T17:10:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/11215/2020-07-13T11:13:26+02:00https://staging.pauljanssenfuturelab.eu/Resource/jak-inhibitors-goreschi-nat-immunol-2009/2019-02-14T17:44:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/details-clinical-studies-filgotinib-galapagos-website/2019-02-14T17:47:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-us9707237b2/2019-02-21T13:12:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/complete-list-inid-codes-wipo/2019-02-21T18:57:11+02:00https://staging.pauljanssenfuturelab.eu/Resource/clarification-international-patent-classification-wipo/2019-02-21T19:03:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/mayne-v-merck/2019-02-28T15:47:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/msd-press-release-noxafil/2019-02-27T17:18:20+02:00https://staging.pauljanssenfuturelab.eu/Resource/scorzoni-front-in-micr-2017-new-advances-antifungal-therapy/2019-02-27T17:25:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/what-is-inter-partes-review-ipr/2019-02-27T17:47:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/kai-et-al-chem-pharm-bull-1996-443568-571/2020-07-13T14:09:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/msd-patent-us8263600/2020-07-13T14:08:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/mayne-patent-us6881745/2019-02-27T18:15:02+02:00https://staging.pauljanssenfuturelab.eu/Resource/inter-partes-review-and-ptab-review/2019-02-28T15:45:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/review-jak-inhibitors-developed-baker-ann-rheum-dis-2017/2020-07-13T13:55:23+02:00https://staging.pauljanssenfuturelab.eu/Resource/licence-agreement-generator/2019-03-28T13:26:54+02:00https://staging.pauljanssenfuturelab.eu/Resource/clinical-development-on-campus-extended-course-intro/2019-06-07T11:21:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/jasmijn-tim-zonmw-grant-futurelab/2019-06-07T15:12:01+02:00https://staging.pauljanssenfuturelab.eu/Resource/jinek_crspr2012/2019-07-31T23:20:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/cong_crispr_2013/2019-07-29T16:32:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/doudna_crispr_us10266850b2/2019-07-29T16:32:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/zhang_crispr_us8697359b1/2019-07-29T16:31:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/chdr-icd-template/2019-06-14T15:30:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/chdr-clinical-study-protocol/2019-06-14T15:30:32+02:00https://staging.pauljanssenfuturelab.eu/Resource/euipo-european-union-intellectual-property-office/2019-06-19T12:23:21+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-united-states-patent-and-trademark-office/2019-06-19T12:26:25+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-orphan-drug-designation/2019-06-19T14:13:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-orphan-drug-designation/2019-06-19T14:15:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-patent-and-exclusivity/2019-06-19T14:25:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-pair/2019-10-16T11:30:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/filgotinib-us-patent-9707237b2/2020-07-13T11:14:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/filigotinib-eu-patent/2020-07-13T13:27:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-dossier-us201313842859/2020-01-19T00:31:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/epr-dossier-us8697359/2020-01-19T00:30:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/jinek_crispr_wo2013-176772a1/2019-07-29T16:29:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/zhang_crispr_wo2014093661/2019-07-29T16:29:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/crispr-patent-battle-goes-to-court/2019-07-18T11:15:33+02:00https://staging.pauljanssenfuturelab.eu/Resource/crispr-oral-arguments-on-dec-6-2016-part-1/2019-07-18T11:18:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/crispr-oral-arguments-on-dec-6-2016-part-2/2019-07-18T11:17:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/13269/2019-08-22T12:34:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/licensing_1_mamaloc_thebreast_2017/2019-09-12T11:41:44+02:00https://staging.pauljanssenfuturelab.eu/Resource/licensing_2_hamers_espacenet/2019-09-05T11:41:49+02:00https://staging.pauljanssenfuturelab.eu/Resource/licensing_2_nanobodies_nanomedicine_2013/2019-09-05T11:44:06+02:00https://staging.pauljanssenfuturelab.eu/Resource/licensing_3_xcr_technology/2019-09-05T15:44:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/grimes-lancet-2005-gcp-a-bronze-standard/2019-09-05T15:49:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/eichler-nature-reviews-2013-the-risks-of-risk-aversion/2021-10-08T15:29:17+02:00https://staging.pauljanssenfuturelab.eu/Resource/neumodx-molecular-systems/2019-09-05T16:26:08+02:00https://staging.pauljanssenfuturelab.eu/Resource/xcr-diagnostics/2019-09-05T16:27:42+02:00https://staging.pauljanssenfuturelab.eu/Resource/breast-cancer-facts-figures-2017-2018/2019-09-12T11:43:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/european-patent-register-ep2445911/2019-09-19T10:50:42+02:00https://staging.pauljanssenfuturelab.eu/Resource/licensing-1-radioactive-seed-localization/2019-09-19T16:05:08+02:00https://staging.pauljanssenfuturelab.eu/Resource/licensing-1-southern-scientific-i-125-seed-company/2019-09-19T16:31:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/lundbeck-escitalopram-patent-ep0347066b1/2019-09-24T17:10:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/opinion-house-of-lords-of-25-february-2009-about-validity-escitalopram-patent/2019-09-23T11:38:26+02:00https://staging.pauljanssenfuturelab.eu/Resource/stereochemistry/2019-09-23T14:23:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/why-lundbecks-patent-was-inventive-the-various-ways-available-to-separate-the-enantiomers/2019-09-24T14:36:31+02:00https://staging.pauljanssenfuturelab.eu/Resource/german-bgh-about-the-validity-of-lundbecks-spc/2019-09-24T15:50:44+02:00https://staging.pauljanssenfuturelab.eu/Resource/13818/2019-09-24T16:15:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/epo-guidelines-about-inventive-step/2019-09-24T16:55:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/h-lundbeck-a-s/2019-09-25T15:57:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/sally-shorthose-bird-bird-intellectual-property-contracts-and-disputes-in-life-sciences/2019-10-01T13:10:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/fenwick-west-llp-patent-litigation-for-high-technology-and-life-sciences-companies/2019-10-01T13:11:44+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-subject-matter-eligibility/2019-10-01T13:12:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/term-sheet-for-license-agreement/2019-10-03T15:53:06+02:00https://staging.pauljanssenfuturelab.eu/Resource/novelty-requirements-in-eu-read-epc-article-54/2019-10-09T11:42:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/novelty-requirements-in-usa-read-usa-35-usc-article-102/2019-10-09T11:43:49+02:00https://staging.pauljanssenfuturelab.eu/Resource/getting-started-with-espacenet/2019-10-16T13:42:54+02:00https://staging.pauljanssenfuturelab.eu/Resource/directly-to-espacenet-search/2019-10-16T13:51:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/getting-started-with-pair/2019-10-16T11:29:25+02:00https://staging.pauljanssenfuturelab.eu/Resource/getting-started-with-eu-patent-register/2019-10-16T13:48:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/directly-to-eu-patent-register-advanced-search/2019-10-16T13:49:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/how-to-espacenet-search/2019-10-16T14:26:39+02:00https://staging.pauljanssenfuturelab.eu/Resource/14611/2019-10-31T16:45:15+02:00https://staging.pauljanssenfuturelab.eu/Resource/sirius-medical/2019-11-07T16:50:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/endomag/2019-11-07T16:53:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/cianna-medical/2019-11-07T16:54:25+02:00https://staging.pauljanssenfuturelab.eu/Resource/protecting-products-vs-platforms-sherkow-nature-biotech-2016/2019-11-12T15:21:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/isr-galapagos/2019-11-29T15:02:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/international-patent-classification-ipc/2019-11-29T16:34:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/written-opinion-galapagos/2019-11-29T17:41:23+02:00https://staging.pauljanssenfuturelab.eu/Resource/iper-galapagos/2019-11-29T16:41:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/mayne-patent-us6881745-2/2020-08-27T09:25:56+02:00https://staging.pauljanssenfuturelab.eu/Resource/maynes-complaint/2020-01-13T16:27:34+02:00https://staging.pauljanssenfuturelab.eu/Resource/human-nature-crispr/2020-01-19T01:20:12+02:00https://staging.pauljanssenfuturelab.eu/Resource/annual-report-ccmo-2010/2021-01-22T15:14:24+02:00https://staging.pauljanssenfuturelab.eu/Resource/amgen-457-patent/2020-03-07T03:43:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/amgen-165-patent/2020-03-07T03:47:54+02:00https://staging.pauljanssenfuturelab.eu/Resource/amgen-741-patent/2020-03-07T03:48:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/regeneron-sanofi-640-patent/2020-03-07T03:47:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-to-clarify-guidance-on-written-description-of-antibodies-2018/2020-03-07T03:52:55+02:00https://staging.pauljanssenfuturelab.eu/Resource/supreme-court-of-the-us-amgen-vs-sanofi-regeneron-2018/2020-03-07T03:56:26+02:00https://staging.pauljanssenfuturelab.eu/Resource/the-pcsk9-decade-j-of-lipid-research-2012/2020-03-07T12:14:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/de-visser-et-al-nature-biotechnology-volume-38-pages14-182020/2020-03-26T08:30:56+02:00https://staging.pauljanssenfuturelab.eu/Resource/maynes-pharma-int-complaint-against-msd-2015/2020-07-13T14:09:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/uspto-2018-inter-partes-review-ptab/2020-07-13T14:16:13+02:00https://staging.pauljanssenfuturelab.eu/Resource/mrs-aliki-nichogiannopoulou-full-interview/2020-10-02T14:08:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/pair/2020-08-26T13:51:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/european-patent-register/2020-09-02T16:40:53+02:00https://staging.pauljanssenfuturelab.eu/Resource/espacenet/2020-08-26T13:50:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-calculator/2020-08-31T15:27:20+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-ep3214091b1/2020-09-07T13:22:25+02:00https://staging.pauljanssenfuturelab.eu/Resource/boots-et-al-stimulation-programs-for-pediatric-drug-research/2020-09-11T10:55:45+02:00https://staging.pauljanssenfuturelab.eu/Resource/ratiopharm-ep-clopidogrel-nl/2020-09-11T16:31:21+02:00https://staging.pauljanssenfuturelab.eu/Resource/avi-biopharma-and-eleos-announce-cross-license-agreement-for-p53-therapeutics/2020-09-13T17:09:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/biopharma-royalty-rate-survey-a-review-of-the-global-biopharmaceutical-royalty-rates-and-deal-terms-survey-licensing-executives-society-u-s-a-and-canada-inc-and-licensing/2020-09-13T17:47:11+02:00https://staging.pauljanssenfuturelab.eu/Resource/license-agreement-generator/2021-04-19T15:53:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/van-der-vaart-et-al-reduction-in-morbidity-of-rotavirus-induced-diarrhoea-in-mice-by-yeast-produced-monovalent-llama-derived-antibody-fragments-vaccine-2016/2020-09-14T11:57:12+02:00https://staging.pauljanssenfuturelab.eu/Resource/icddr-annual-report-2006/2020-09-14T11:59:27+02:00https://staging.pauljanssenfuturelab.eu/Resource/chitale-et-al-nature-biotechnology-2016-closing-the-deal/2020-09-16T10:48:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/harlin-and-oconnor-nature-biotechnology-2008/2020-09-16T10:51:51+02:00https://staging.pauljanssenfuturelab.eu/Resource/press-release-2019-gilead-and-galapagos/2020-09-16T11:07:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/sarker-et-al-gasteroenterology-2013/2020-09-16T11:51:17+02:00https://staging.pauljanssenfuturelab.eu/Resource/en-kg-09-1115-sanofi-ratiopharm-ep-clopidogrel/2020-09-16T12:00:41+02:00https://staging.pauljanssenfuturelab.eu/Resource/sarker-et-al-gasteroenterology-2013-2/2020-09-16T12:07:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/galapagos-and-gilead-sciences-option-license-and-collaboration-agreement-ocr/2020-09-16T16:11:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/joosten-et-al-2013-microbial-cell-factories-the-production-of-antibody-fragments-and-antibody-fusion-proteins/2020-09-18T09:11:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/special-class-of-antibodies-prof-raymond-hamers/2020-09-18T10:25:07+02:00https://staging.pauljanssenfuturelab.eu/Resource/cross-license-avi-pharma-and-eleos-2007/2020-09-28T17:16:34+02:00https://staging.pauljanssenfuturelab.eu/Resource/memorandum-opinion-district-court-of-delaware-august-28-2019-invalidating-amgens-patents/2020-09-29T14:16:25+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-us8062640b2-regeneron-sanofi-ocr/2020-09-29T14:17:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/ratner-nature-biotechnology-2017-amgen-cholesterol-antibody-feud-could-kill-ip-rule/2020-09-29T14:23:45+02:00https://staging.pauljanssenfuturelab.eu/Resource/2012-bmj-hitchings-making-medicines-evergreen/2020-09-29T14:34:03+02:00https://staging.pauljanssenfuturelab.eu/Resource/lundbeck-patent-ep0347066b1-ocr/2020-09-29T14:34:24+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-us8829165b2-amgen-ocr/2020-09-29T15:19:51+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-us8859741b2-amgen-ocr/2020-09-29T15:21:06+02:00https://staging.pauljanssenfuturelab.eu/Resource/crucell-receives-two-european-patents-covering-its-per-c6-and-advac-technology/2020-09-29T16:21:46+02:00https://staging.pauljanssenfuturelab.eu/Resource/cevec-opposition-against-patent-ep1161548-ocr/2020-09-29T16:22:13+02:00https://staging.pauljanssenfuturelab.eu/Resource/decision-epo-on-opposition-cevec-against-patent-ep1161548/2020-09-29T16:22:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/ep1108787b2-per-c6-for-influenza-vaccines-ocr/2020-09-29T16:23:55+02:00https://staging.pauljanssenfuturelab.eu/Resource/ep1161548b2-per-c6-for-recombinant-proteins-ocr/2020-09-29T16:24:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/ep1349926b1-per-c6-for-ad35-based-vaccines-ocr/2020-09-29T16:24:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/fallaux-et-al-human-gene-therapy-1998-per-c6-cell-line/2020-09-29T16:25:08+02:00https://staging.pauljanssenfuturelab.eu/Resource/response-crucell-to-opposition-cevec-against-ep1161548/2020-09-29T16:25:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/transcripts-fda-2001-testimony-van-der-eb-ocr/2020-09-29T16:26:07+02:00https://staging.pauljanssenfuturelab.eu/Resource/wo9700326a1-per-c6-for-gene-therapy-ocr/2020-09-29T16:28:21+02:00https://staging.pauljanssenfuturelab.eu/Resource/van-dam-et-al-nature-medicine-2011/2020-09-30T08:57:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/lamberts-et-al-clinical-cancer-research-2017/2020-09-30T08:58:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/genentech-patent-anti-vegf-antibodies-ep1325932b1-ocr/2020-09-30T09:05:01+02:00https://staging.pauljanssenfuturelab.eu/Resource/genentech-patent-anti-vegf-antibodies-with-fluorescent-label-ep1787999b1/2020-09-30T09:06:02+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-wo2011098101a1-method-and-device-for-multi-spectral-photonic-imaging/2020-09-30T09:08:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/surgvision-roche-term-sheet/2020-10-01T11:48:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/press-release-from-crucell-october-6-2004/2020-09-30T19:35:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/full-interview-ton-van-der-hoven-surgvision/2020-10-01T11:13:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-examination-procedures-template-empty/2020-10-02T10:32:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/patent-analysis-form-surgvision-empty-template/2020-10-02T10:31:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/protecting-your-inventions-the-patent-system-webber-2013/2021-01-25T15:40:07+02:00https://staging.pauljanssenfuturelab.eu/Resource/presentation-maurits-westerik/2021-02-04T09:48:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/the-ablynx-vs-unilver-dispute/2021-02-08T15:30:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/ablynx-unilever-judgment-coa-english-translation/2021-02-15T09:42:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/adam-cohen-talk-2-slides/2021-03-24T12:36:24+02:00https://staging.pauljanssenfuturelab.eu/Resource/adam-cohen-a-history-of-drug-development-slides/2021-03-24T12:35:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/johan-garssen-modern-medical-nutrition-development-slides/2021-03-24T12:38:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/understanding-the-basics-of-patenting-chitale-et-al-2020/2021-04-28T15:43:15+02:00https://staging.pauljanssenfuturelab.eu/Resource/nature-2021-its-time-to-consider-a-patent-reprieve-for-covid-vaccines/2021-05-14T13:03:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/market-approval-online-melatonine-assessment-template/2021-08-13T12:36:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/all-aidacs-opinions/2021-11-10T15:38:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/sirturo-package-ema/2021-08-13T15:44:56+02:00https://staging.pauljanssenfuturelab.eu/Resource/sirturo-package-fda/2021-08-13T15:44:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/bedaquiline-for-mdr-tb-package-template/2021-08-13T15:43:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/vollmann-j-and-winau-r-nurembergs-doctors-trial-informed-consent-in-human-experimentation-before-the-nuremberg-code-bmj-1996-3131445-1149/2021-08-13T15:53:11+02:00https://staging.pauljanssenfuturelab.eu/Resource/borysowski-j-et-al-ethics-review-in-compassionate-use-bmc-medicine-2017-15136/2021-08-13T15:55:26+02:00https://staging.pauljanssenfuturelab.eu/Resource/efsa-journal-2010-821467-scientific-opinion-on-the-substantiation-of-health-claims-related-to-melatonin-and-alleviation-of-subjective-feelings-of-jet-lag-id1953-and-reduction-of-sleep-onset-lat/2021-08-13T16:10:58+02:00https://staging.pauljanssenfuturelab.eu/Resource/efsa-journal-2011-962241-scientific-opinion-on-the-substantiation-of-health-claims-related-to-melatonin-and-reduction-of-sleep-onset-latency-id-1698-1780-4080-pursuant-to-article-131-af-regu/2021-09-16T09:55:31+02:00https://staging.pauljanssenfuturelab.eu/Resource/europe-circadin-product-information/2021-08-13T16:04:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/europe-slenyto-product-information/2021-08-13T16:06:14+02:00https://staging.pauljanssenfuturelab.eu/Resource/despite-fda-warning-letters-melatonin-laced-food-and-beverage-market-grows-sleep-review/2021-08-13T16:06:57+02:00https://staging.pauljanssenfuturelab.eu/Resource/guidance-for-industry-considerations-regarding-substances-added-to-foods-including-beverages-and-dietary-supplements/2021-08-13T16:08:11+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-warning-letter-center-for-food-safety-and-applied-nutrition-bebida-beverage-company/2021-08-13T16:09:07+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-warning-letter-center-for-food-safety-and-applied-nutrition-gold-crown-natural-products/2021-08-13T16:09:30+02:00https://staging.pauljanssenfuturelab.eu/Resource/bedaquiline-janssen-presentation/2021-08-13T16:15:19+02:00https://staging.pauljanssenfuturelab.eu/Resource/bedaquiline-summary-minutes/2021-08-13T16:16:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/bedaquiline-fda-label/2021-08-13T16:18:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/edward-cox-m-d-m-p-h-and-katherine-laessig-m-d-2014-fda-approval-of-bedaquiline-the-benefit-risk-balance-for-drug-resistant-tuberculosis-n-engl-j-med-3718-689/2021-08-13T16:19:47+02:00https://staging.pauljanssenfuturelab.eu/Resource/berger-r-l-nazi-science-the-dachau-hypothermia-experiments-nejm-1990-322201435-1440/2021-08-16T09:36:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/eu-summary-of-product-characteristics-bedaquiline/2021-08-16T12:12:54+02:00https://staging.pauljanssenfuturelab.eu/Resource/bedaquiline-exercise-completing-the-tpp-template/2021-11-22T10:07:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/bedaquiline-exercise-completing-the-tpp-answer/2021-11-22T10:07:31+02:00https://staging.pauljanssenfuturelab.eu/Resource/target-product-profile-for-bedaquiline-sirturo-other-topics-template/2021-11-22T10:09:38+02:00https://staging.pauljanssenfuturelab.eu/Resource/auspar-attachment-2-extract-from-the-clinical-evaluation-report-for-eliglustat-as-tartrate/2021-08-16T13:27:33+02:00https://staging.pauljanssenfuturelab.eu/Resource/regulatory-evaluation-of-glybera-in-europe-%e2%80%92-two-committees-one-mission-nature-melchiorri-et-al-2013/2021-09-27T10:42:35+02:00https://staging.pauljanssenfuturelab.eu/Resource/tyndall-et-al-2017-the-target-product-profile-as-a-tool-for-regulatory-communication-advantageous-but-underused-nature-com-16-156/2021-08-18T10:09:45+02:00https://staging.pauljanssenfuturelab.eu/Resource/breder-et-al-2017-whats-the-regulatory-value-of-a-target-product-profile-trends-in-biotechnology-vol-35-7-576/2021-08-18T10:10:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/tga-guidance-assessed-listed-medicines-evidence-chapter-3-indications-guidelines/2021-08-18T10:13:23+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-draft-guidance-indications-and-usage-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/2021-08-18T10:13:53+02:00https://staging.pauljanssenfuturelab.eu/Resource/c-hutchison-et-al-2018-challenges-in-conducting-clinical-trials-in-rare-diseases-regulatory-rapporteur-vol15-2-18-22/2021-08-18T10:31:15+02:00https://staging.pauljanssenfuturelab.eu/Resource/classification-ema-link/2021-08-18T13:48:40+02:00https://staging.pauljanssenfuturelab.eu/Resource/classification-fda-link/2021-08-18T13:49:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/andries-et-al-science-2005-a-diarylquinoline-drug-actie-on-the-atp-synthase-of-mycobacterium-tuberculosis/2021-08-19T13:50:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/cole-and-alzari-science-2005-tb-a-new-target-science/2021-08-19T13:51:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-website/2021-08-20T10:31:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/market-approval-navigator-man/2023-03-16T16:53:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/georgiou-et-al-eur-j-pharmacol-nutrion-and-pharma-2010-narrowing-the-gap/2021-08-30T15:56:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/michael-tansey-2014-the-target-product-profile/2021-08-30T16:05:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-guidance-target-product-profile/2021-08-30T16:12:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/who-ttp/2021-08-30T16:14:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/who-the-right-to-health/2021-09-16T09:43:36+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-expanded-access/2021-09-16T09:44:00+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-right-to-try/2021-09-16T09:44:20+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-compassionate-use/2021-09-16T09:44:45+02:00https://staging.pauljanssenfuturelab.eu/Resource/efsa-guidance-biological-relevance-assessment-efsa-journal-2017-4970/2021-09-16T09:48:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/20121128-aidac-t1-transcript/2021-09-16T10:15:53+02:00https://staging.pauljanssenfuturelab.eu/Resource/genentech-leuven-agreement/2021-09-23T16:58:43+02:00https://staging.pauljanssenfuturelab.eu/Resource/record-a-powerpoint-presentation/2021-10-01T10:25:59+02:00https://staging.pauljanssenfuturelab.eu/Resource/regnstrom-et-al-2010-factors-associated-with-success-of-market-authorisation-applications-for-pharmaceutical-drugs-submitted-to-the-ema-eur-j-clin-pharmacol-6639-48/2021-10-01T16:01:29+02:00https://staging.pauljanssenfuturelab.eu/Resource/hofer-et-al-2015-impact-of-scientific-advice-from-the-ema-nature-reviews-drug-discovery-14302-303/2021-10-01T16:04:10+02:00https://staging.pauljanssenfuturelab.eu/Resource/spostare-starters-pack/2021-10-04T13:28:09+02:00https://staging.pauljanssenfuturelab.eu/Resource/koshland-science-1987-tpa-and-pdq/2021-10-04T13:42:15+02:00https://staging.pauljanssenfuturelab.eu/Resource/kowey-et-al-jama-1988-the-tpa-controversy-and-the-drug-approval-process/2021-10-04T13:41:53+02:00https://staging.pauljanssenfuturelab.eu/Resource/putzeist-et-al-nat-drg-rev-disc-2012-factors-influencing-non-approval-of-new-drugs-in-europe/2021-10-04T13:42:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/sun-science-1987-fda-puts-new-heart-drug-on-hold/2021-10-04T13:42:34+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-press-release-7-april-2021/2021-10-08T10:06:20+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-press-release-27-april-2021/2021-10-08T10:06:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-chmp-epar-public-assessment-report-pdf/2021-10-08T15:04:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-approval-history/2021-10-08T15:04:28+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-advisory-committee-meeting/2021-10-08T15:04:39+02:00https://staging.pauljanssenfuturelab.eu/Resource/moderna-ema-chmp-epar-public-assessment-report/2021-10-08T15:06:16+02:00https://staging.pauljanssenfuturelab.eu/Resource/moderna-fda-approval-history/2021-10-08T15:06:54+02:00https://staging.pauljanssenfuturelab.eu/Resource/moderna-fda-advisory-committee-meeting/2021-10-08T15:07:31+02:00https://staging.pauljanssenfuturelab.eu/Resource/van-gerven-and-bonelli-2019-br-j-clin-pharm-commentary-on-the-ema-guideline-on-strategies-to-identify-and-mitigate-risks-for-first-in-human-and-early-clinical-trials-with-investigational-medicinal-p/2021-10-08T15:31:05+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-guidance-guidance-for-industry-antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency/2021-10-08T15:38:01+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-guideline-ema-117973-2021-reflection-paper-on-the-regulatory-requirements-for-vaccines-intended-to-provide-protection-against-variant-strains-of-sars-cov-2/2021-10-08T15:38:33+02:00https://staging.pauljanssenfuturelab.eu/Resource/learning-lessons-from-pfizers-usd-800-million-failure/2021-10-13T08:59:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/the-new-york-times-26-nov-2020-astrazeneca-admits-error-with-vaccine/2021-10-13T09:18:48+02:00https://staging.pauljanssenfuturelab.eu/Resource/rb3285-impd/2021-10-15T10:18:02+02:00https://staging.pauljanssenfuturelab.eu/Resource/view-patent-us4752603a/2021-10-27T09:44:13+02:00https://staging.pauljanssenfuturelab.eu/Resource/view-genentech-leuven-agreement-in-separate-tab/2021-11-01T14:09:22+02:00https://staging.pauljanssenfuturelab.eu/Resource/pennica-et-al-nature-1983-cloning-and-expression-of-human-t-pa/2021-10-27T11:01:44+02:00https://staging.pauljanssenfuturelab.eu/Resource/view-mullard-nat-rev-drug-disc-2021-gene-therapy-and-toxicity-issues/2021-11-01T14:12:04+02:00https://staging.pauljanssenfuturelab.eu/Resource/rivaroxabananevaluationofitscardiovascularbenefit-riskprofileacrossindicationsbasedonnumbersneededtotreatorharmandonclinicallymeaningfulendpointcomparisons/2021-11-10T13:39:52+02:00https://staging.pauljanssenfuturelab.eu/Resource/fda-search-page/2021-11-29T11:12:32+02:00https://staging.pauljanssenfuturelab.eu/Resource/ema-search-page/2021-11-29T11:13:21+02:00https://staging.pauljanssenfuturelab.eu/Resource/ich-website/2021-11-29T11:19:11+02:00https://staging.pauljanssenfuturelab.eu/Resource/google-website/2021-11-29T11:20:45+02:00https://staging.pauljanssenfuturelab.eu/Resource/harinder-singh-chahal-2021-contents-of-us-food-and-drug-administration-refuse-to-file-letters-for-newdrug-applications-and-efficacy-supplements-and-their-public-disclosure-by-applicants-jamainterna/2021-12-02T13:24:37+02:00https://staging.pauljanssenfuturelab.eu/Resource/hover-et-al-2015-impact-of-scientific-advice-from-the-european-medicines-agency-nature-reviews/2021-12-02T13:24:55+02:00https://staging.pauljanssenfuturelab.eu/Resource/test-resource/2023-10-05T11:27:01+02:00